Dubuque Bank & Trust Co. Has $11.48 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Dubuque Bank & Trust Co. trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 7.3% during the third quarter, HoldingsChannel.com reports. The firm owned 70,275 shares of the company’s stock after selling 5,559 shares during the period. Johnson & Johnson makes up approximately 1.6% of Dubuque Bank & Trust Co.’s portfolio, making the stock its 12th biggest holding. Dubuque Bank & Trust Co.’s holdings in Johnson & Johnson were worth $11,480,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JNJ. RKL Wealth Management LLC raised its position in shares of Johnson & Johnson by 2.1% during the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after acquiring an additional 1,010 shares during the last quarter. Geller Advisors LLC raised its position in shares of Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares during the last quarter. Simon Quick Advisors LLC raised its position in shares of Johnson & Johnson by 296.9% during the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after acquiring an additional 6,537 shares during the last quarter. Lokken Investment Group LLC raised its position in shares of Johnson & Johnson by 1.6% during the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after acquiring an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP raised its position in shares of Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after acquiring an additional 525 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. Citigroup raised their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Sanford C. Bernstein lowered their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Wednesday. The stock has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business’s 50 day moving average is $175.98 and its 200 day moving average is $171.06.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.12. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.